ロード中...
非小细胞肺癌中驱动基因状态与免疫治疗相关性的研究进展
In recent years, the checkpoint inhibitors targeted programmed cell death 1 (PD-1) and its ligand 1 (PD-1 ligand, PD-L1) achieved landmark significance in treating a variety of cancers including non-small cell lung cancer (NSCLC). However, current immunotherapy is not precise enough, only 15%-20% of...
保存先:
| 出版年: | Zhongguo Fei Ai Za Zhi |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
中国肺癌杂志编辑部
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6500499/ https://ncbi.nlm.nih.gov/pubmed/31014442 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2019.04.06 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|